All In Biotech

Drug Trial Radar · NCT05969223

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects With Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis

Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 214 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

214

Actual

Start

Aug 10, 2023

Primary completion

Jan 22, 2025

Study completion Nov 28, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 studies by disease location, participants with moderate to severe genital psoriasis (Study-G) and moderate to severe scalp psoriasis (Study-S). In both studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Genital Psoriasis
  • Scalp Psoriasis

Interventions

  • RisankizumabDrug

    Subcutaneous injection

  • Placebo for RisankizumabDrug

    Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16Time frame: Week 16
  2. Study-S: Percentage of Participants With Achievement of Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16Time frame: Week 16

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Medical Dermatology Specialists /ID# 262915

    Phoenix, Arizona

  • Alliance Dermatology and Mohs Center /ID# 255846

    Phoenix, Arizona

  • Banner University Medicine Dermatology /ID# 255845

    Tucson, Arizona

  • Private Practice - Dr. Tooraj Raoof /ID# 255334

    Encino, California

  • Dermatology Research Associates /ID# 255347

    Los Angeles, California

  • Clinical Trials Research Institute /ID# 264555

    Thousand Oaks, California

  • Florida Academic Dermatology Center /ID# 264065

    Coral Gables, Florida

  • Skin Care Research - Hollywood /ID# 255394

    Hollywood, Florida

  • GSI Clinical Research, LLC /ID# 255472

    Margate, Florida

  • Skin and Cancer Associates, LLP /ID# 255506

    Miami, Florida

  • Sullivan Dermatology /ID# 264067

    Miami, Florida

  • Renstar Medical Research /ID# 255339

    Ocala, Florida

  • Hamilton Research, LLC /ID# 255409

    Alpharetta, Georgia

  • Treasure Valley Medical Research /ID# 255671

    Boise, Idaho

  • DeNova Research /ID# 264063

    Chicago, Illinois

  • Arlington Dermatology /ID# 255330

    Rolling Meadows, Illinois

  • The Indiana Clinical Trials Center /ID# 255333

    Plainfield, Indiana

  • Dermatology Partners of Leawood /ID# 263244

    Leawood, Kansas

  • DermAssociates - Rockville /ID# 263252

    Rockville, Maryland

  • Skin Specialists /ID# 262929

    Omaha, Nebraska

  • Skin Cancer and Dermatology Institute (SCDI) /ID# 264570

    Sparks, Nevada

  • Care Access - Hoboken /ID# 264066

    Hoboken, New Jersey

  • Forest Hills Dermatology Group @ Union Turnpike /ID# 255346

    Kew Gardens, New York

  • Schweiger Dermatology, P.C. /ID# 255336

    New York, New York

  • Darst Dermatology /ID# 255848

    Charlotte, North Carolina

  • Wright State Physicians Health Center /ID# 255395

    Fairborn, Ohio

  • Apex Clinical Research Center /ID# 263432

    Mayfield Heights, Ohio

  • Oregon Dermatology and Research Center /ID# 255670

    Portland, Oregon

  • Oregon Medical Research Center /ID# 255332

    Portland, Oregon

  • Studies in Dermatology LLC /ID# 262989

    Cypress, Texas

  • Modern Research Associates /ID# 263234

    Dallas, Texas

  • Center for Clinical Studies - Houston (Binz) /ID# 255396

    Houston, Texas

  • U.S. Dermatology Partners Longview /ID# 266325

    Longview, Texas

  • Progressive Clinical Research - San Antonio /ID# 263255

    San Antonio, Texas

  • Center for Clinical Studies Webster TX /ID# 255518

    Webster, Texas

  • Care Access - Danville /ID# 266300

    Danville, Virginia

  • Center for Excellence in Dermatology /ID# 264647

    Kennewick, Washington

  • North Sound Dermatology /ID# 264565

    Mill Creek, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.